Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck KGAA

www.emdgroup.com/en

Latest From Merck KGAA

Pipeline Watch: Phase III Progress With Lefamulin, Dupilumab, Patisiran

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Approvals Pipeline Watch

Merck KGaA/Pfizer Get Europe OK For Bavencio In Rare Skin Cancer

The Merkel cell carcinoma area is very niche but getting approval means that Merck and Pfizer can now prepare to compete with the likes of Opdivo and Keytruda in the European PD-1/PD-L1 space.

Approvals ImmunoOncology

Prima BioMed Carves A Niche In Busy IO Pipeline

Emerging Company Profile: Prima BioMed, a biotech developing immuno-oncology medicines, has been patiently waiting in the wings. Now, with three of its LAG-3 drug candidates partnered with pharma players, the company is ready to take center stage.

StartUps and SMEs ImmunoOncology

Pipeline Watch: Phase III Readouts For Gilenya, Duvelisib, Trimbow

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register